BETA-ADRENERGIC AGONISTS SUPPRESS CHRONIC/RELAPSING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (CREAE) IN LEWIS RATS
BETA-ADRENERGIC AGONISTS SUPPRESS CHRONIC/RELAPSING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (CREAE) IN LEWIS RATS
复制标题
DOI：
10.1016/0165-5728(94)00153-f
复制
发表时间：
1995-02-01
影响因子：
3.3
通讯作者：
CHELMICKASCHORR, E
中科院分区：
文献类型：
--
作者：
WIEGMANN, K;MUTHYALA, S;CHELMICKASCHORR, E
慢性/复发性实验性过敏性脑脊髓炎（CREAE）是复发/缓解型多发性硬化症的动物模型。使用β-肾上腺素能激动剂异丙肾上腺素或β(2)-肾上腺素能激动剂特布他林治疗可显着抑制CREAE Lewis 大鼠的首次急性发作和复发次数。即使在 CREAE 第一次急性发作后开始使用 P-肾上腺素能激动剂治疗，复发次数也会减少。与健康对照或注射 CFA 的大鼠相比，CREAE 大鼠脾细胞上的 β-肾上腺素能受体数量显着增加。特布他林治疗 CREAE 大鼠可将脾细胞受体数量降至正常值。
Chronic/relapsing experimental allergic encephalomyelitis (CREAE) serves as an animal model for relapsing/remitting multiple sclerosis. Treatment with the beta-adrenergic agonist isoproterenol or the beta(2)-adrenergic agonist terbutaline significantly suppressed both the first acute attack and the number of relapses in CREAE Lewis rats. The number of relapses was decreased even when treatment with P-adrenergic agonist was started after the onset of the first acute attack of CREAE. beta-adrenergic receptor number was increased significantly on splenocytes from CREAE rats as compared to healthy controls or CFA-injected rats. Terbutaline treatment of CREAE rats lowered the splenocyte receptor number to normal values.